Sodium‐Glucose Cotransporter‐2 Inhibitors and Stroke Risk in Patients With Atrial Fibrillation
SGLT2-I use in patients with AF is associated with lower risks of stroke and other cardiovascular and non-cardiovascular outcomes. Future prospective research is needed to validate these findings.
Authors
- Kwan Lee (ORCID: https://orcid.org/0000-0001-6302-9925)
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
- Hoang Nhat Pham (ORCID: https://orcid.org/0000-0001-8412-0082)
- Reza Arsanjani (ORCID: https://orcid.org/0000-0001-7081-4286)
- Dan Sorajja (ORCID: https://orcid.org/0000-0003-1976-6420)
- Justin Z. Lee (ORCID: https://orcid.org/0000-0003-2823-9243)
- Mahmoud Hassan Abdelnabi (ORCID: https://orcid.org/0000-0001-8016-9049)
- Ramzi Ibrahim (ORCID: https://orcid.org/0000-0003-0124-9513)
- Eiad Habib (ORCID: https://orcid.org/0000-0003-4708-0039)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Luis Scott
- Steven J. Lester
- Gerald Lim
- Xuan Ci Mee (ORCID: https://orcid.org/0009-0005-3878-5506)
Institutions
- Cleveland Clinic (US)
- University of Arizona (US)
- WinnMed (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Cardiovascular Electrophysiology
- Published
- 2025-06-12
- DOI
- https://doi.org/10.1111/jce.16739
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47